{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intranasal+esketamine&page=2", "query": { "intervention": "Intranasal esketamine", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intranasal+esketamine&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-29T12:15:38.512Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07716098", "title": "A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Depressive Disorder, Treatment-Resistant" ], "interventions": [ { "name": "Esketamine 56 mg", "type": "DRUG" }, { "name": "Esketamine 84 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 348, "start_date": "2026-07-23", "completion_date": "2029-09-12", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-09-29T12:15:38.512Z", "location_count": 7, "location_summary": "Redlands, California • San Diego, California • Marietta, Georgia + 4 more", "locations": [ { "city": "Redlands", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Marietta", "state": "Georgia" }, { "city": "Skokie", "state": "Illinois" }, { "city": "Cedarhurst", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07716098" }, { "nct_id": "NCT01998958", "title": "A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Treatment Resistant Depressive Disorder" ], "interventions": [ { "name": "Esketamine 14 mg", "type": "DRUG" }, { "name": "Esketamine 28 mg", "type": "DRUG" }, { "name": "Esketamine 56 mg", "type": "DRUG" }, { "name": "Esketamine 84 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "20 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "20 Years to 64 Years" }, "enrollment_count": 108, "start_date": "2014-01-27", "completion_date": "2015-09-25", "has_results": true, "last_update_posted_date": "2025-04-29", "last_synced_at": "2026-09-29T12:15:38.512Z", "location_count": 14, "location_summary": "Birmingham, Alabama • Garden Grove, California • Hartford, Connecticut + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Garden Grove", "state": "California" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01998958" }, { "nct_id": "NCT02857777", "title": "Pharmacokinetic, Safety, and Tolerability Study of Intranasally Administered Esketamine in Elderly Japanese, and Healthy Younger Adult Japanese Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Esketamine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "20 Years", "maximum_age": null, "sex": "ALL", "summary": "20 Years and older" }, "enrollment_count": 37, "start_date": "2016-08-09", "completion_date": "2017-01-27", "has_results": false, "last_update_posted_date": "2025-02-03", "last_synced_at": "2026-09-29T12:15:38.512Z", "location_count": 1, "location_summary": "Cypress, California", "locations": [ { "city": "Cypress", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02857777" }, { "nct_id": "NCT07396220", "title": "Psychotherapy Combined With Intranasal Esketamine for the Treatment of Suicidal Ideation", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Suicidal Ideation" ], "interventions": [ { "name": "Naturalistic Intranasal Esketamine", "type": "OTHER" }, { "name": "Brief Cognitive Behavioral Therapy for Suicide Prevention", "type": "BEHAVIORAL" } ], "intervention_types": [ "OTHER", "BEHAVIORAL" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 56, "start_date": "2026-01-09", "completion_date": "2029-01", "has_results": false, "last_update_posted_date": "2026-02-09", "last_synced_at": "2026-09-29T12:15:38.512Z", "location_count": 1, "location_summary": "San Diego, California", "locations": [ { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07396220" }, { "nct_id": "NCT03039192", "title": "54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Depressive Disorder, Major" ], "interventions": [ { "name": "Esketamine", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Standard of Care", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 226, "start_date": "2017-06-09", "completion_date": "2018-12-18", "has_results": true, "last_update_posted_date": "2025-04-29", "last_synced_at": "2026-09-29T12:15:38.512Z", "location_count": 17, "location_summary": "Birmingham, Alabama • Chandler, Arizona • Garden Grove, California + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Garden Grove", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03039192" }, { "nct_id": "NCT03097133", "title": "54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Depressive Disorder, Major" ], "interventions": [ { "name": "Esketamine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Standard of Care", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 230, "start_date": "2017-06-15", "completion_date": "2019-04-11", "has_results": true, "last_update_posted_date": "2025-04-29", "last_synced_at": "2026-09-29T12:15:38.512Z", "location_count": 18, "location_summary": "San Diego, California • Farmington, Connecticut • Miami, Florida + 14 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Farmington", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "North Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03097133" }, { "nct_id": "NCT02611505", "title": "A Study to Assess the Effects of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatic Impairment", "Normal Hepatic Function" ], "interventions": [ { "name": "Esketamine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 24, "start_date": "2015-11-30", "completion_date": "2017-02-27", "has_results": false, "last_update_posted_date": "2025-02-03", "last_synced_at": "2026-09-29T12:15:38.512Z", "location_count": 1, "location_summary": "Knoxville, Tennessee", "locations": [ { "city": "Knoxville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02611505" }, { "nct_id": "NCT02846519", "title": "Pharmacokinetic, Safety, and Tolerability Study of Intranasally Administered Esketamine in Healthy Han Chinese, Korean, Japanese, and Caucasian Participants and the Effects of Rifampin on the Pharmacokinetics of Intranasally Administered Esketamine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Esketamine", "type": "DRUG" }, { "name": "Rifampin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "20 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "20 Years to 55 Years" }, "enrollment_count": 66, "start_date": "2016-02-26", "completion_date": "2016-05-28", "has_results": false, "last_update_posted_date": "2025-04-27", "last_synced_at": "2026-09-29T12:15:38.512Z", "location_count": 1, "location_summary": "Cypress, California", "locations": [ { "city": "Cypress", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02846519" }, { "nct_id": "NCT02133001", "title": "A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who Are Assessed to be at Imminent Risk for Suicide", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Major Depressive Disorder" ], "interventions": [ { "name": "Esketamine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 68, "start_date": "2014-05-23", "completion_date": "2016-02-01", "has_results": true, "last_update_posted_date": "2025-04-29", "last_synced_at": "2026-09-29T12:15:38.512Z", "location_count": 14, "location_summary": "Birmingham, Alabama • San Diego, California • Hartford, Connecticut + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Diego", "state": "California" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02133001" }, { "nct_id": "NCT02497287", "title": "A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Treatment-resistant Depression" ], "interventions": [ { "name": "Esketamine (Intranasal Spray)", "type": "DRUG" }, { "name": "Duloxetine (Oral Antidepressant)", "type": "DRUG" }, { "name": "Escitalopram (Oral Antidepressant)", "type": "DRUG" }, { "name": "Sertraline (Oral Antidepressant)", "type": "DRUG" }, { "name": "Venlafaxine Extended Release (XR) (Oral Antidepressant)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 802, "start_date": "2015-09-30", "completion_date": "2017-10-28", "has_results": true, "last_update_posted_date": "2025-04-29", "last_synced_at": "2026-09-29T12:15:38.512Z", "location_count": 16, "location_summary": "New Haven, Connecticut • Miami, Florida • Marietta, Georgia + 13 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Marietta", "state": "Georgia" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Wichita", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02497287" } ] }